September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Subthreshold laser grid photocoagulation for the treatment of diabetic macular edema
Author Affiliations & Notes
  • Pietro Frascio
    Clinica Oculistica Genova, Genova, Italy
  • Raffaella Rosa
    Clinica Oculistica Genova, Genova, Italy
  • Donatella Musetti
    Clinica Oculistica Genova, Genova, Italy
  • Maria Musolino
    Clinica Oculistica Genova, Genova, Italy
  • Carlo Alberto Cutolo
    Clinica Oculistica Genova, Genova, Italy
  • Carlo Enrico Traverso
    Clinica Oculistica Genova, Genova, Italy
  • Massimo Nicolo
    Clinica Oculistica Genova, Genova, Italy
  • Footnotes
    Commercial Relationships   Pietro Frascio, None; Raffaella Rosa, None; Donatella Musetti, None; Maria Musolino, None; Carlo Alberto Cutolo, None; Carlo Traverso, None; Massimo Nicolo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3247. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Pietro Frascio, Raffaella Rosa, Donatella Musetti, Maria Musolino, Carlo Alberto Cutolo, Carlo Enrico Traverso, Massimo Nicolo; Subthreshold laser grid photocoagulation for the treatment of diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3247.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To evaluate the efficacy and safety of subthreshold laser grid photocoagulation (SLGP) in patients affected by diabetic macular edema (DME).

Methods : For the past decades, laser photocoagulation has been the mainstay of treatment for patients with DME; however, although effective in preserving vision, this form of therapy is of limited effect in restoring lost vision. Recently, anti vascular endothelial growth factor agents and corticosteroids have been approved for the treatment of DME but there are still some questions regarding safety, dose frequency and costs for both the patients and the national health system. Retrospective analysis of the I-maculaweb database selecting patients with DME treated with SLGP. The patients for this study were selected according to the following characteristics: not being able to receive either anti-VEGF agents, due to medical reasons, or corticosteroids being phakic or cortisone responders or among those who did not show any improvement after anti-VEGF injections. 21 eyes of 14 caucasian patients were treated with SLGP using 10 ms, 100 µm single spot, 50% end point management. Initial energy was 100 mW, increases of 25 mW were utilised as needed.
Patients were retreated after a minimum time of 3 months when either the central retinal thickness (CRT) didn’t show any sign of decrease or best corrected visual acuity (BCVA) didn’t increase more than 5 letter. Mean number of SLGP was 1.4±0.75.
Glycosilated Haemoglobin levels were monitored before the treatment and did not differ significantly during the follow-up.

Results : Mean age was 68 years±16.85. Mean CRT at baseline and last follow-up visit was 327.49µ ±27.40 and 312.07 µ ±32.06 respectively (p=0.0045; paired t test). Mean number of ETDRS letter score at baseline and last follow-up visit was 67.43±9.93 and 71.38±10.95 (p=0,0075; paired t test) respectively. Mean follow-up was 11.52 months ±9.02.
No visual and systemic adverse events were experienced after the SLGP.

Conclusions : SLGP might be a safe and useful option in those patients who cannot receive either anti-vegf agents or corticosteroids.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.